



Drug Formulary Update, October 2021 Commercial Programs

Updates to the HealthPartners Commercial Formularies (PreferredRx and GenericsAdvantageRx) are listed below.

Please see www.healthpartners.com/formularies for details.

Updates are effective by October 1 2021.

Drug name	Current Status	New Status	Comments
Arformoterol (Brovana) solution	NF-PA	NF-PA	A standard update, to prefer the equivalent generic.
Arformoterol solution		NF-PA	A new generic, adopting the Brand status.
Bepotastine eye drops		NF-PA	A new generic, adopting the Brand status.
Cyclophosphamide tablets		F	A new FDA-approval, added as a line extension.
Dasiglucagon (Zegalogue)		F	A new FDA-approval.
Elexacaftor/ tezacaftor/ ivacaftor (Trikafta)		F-PA-SP	Adding a new strength, and updating coverage criteria for a younger age group.
Etravirine		F	A new generic, adopting the Brand status.
Etravirine (Intelence)	F	NF	A standard update, to prefer the equivalent generic.
Ferrous gluconate and ferrous sulfate	NF	NF	Iron is no longer listed as a preventative health service, and is being removed from the ACA list. Iron is non-formulary and available as an OTC medication.
Fluoride solution		NF	A new generic, adopting the Brand status.
Freestyle Precision Neo	NC-QL	NC-QL	Updating the quantity limit, to #25 per Rx.
Gabapentin (Neurontin)	NF-QL	NF-PA-QL	Adding PA due to high cost. The generic equivalent remains on formulary.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, NC = Not Covered, SP = Specialty Drug, QL = Quantity Limit. ONC = Oncology medicine. A current formulary status is not shown for new medications.

Drug name	Current Status	New Status	Comments
Infigratinib (Truseltiq)		F-PA-SP-ONC	A new FDA-approval, added with standard oncology coverage criteria.
Isotretinoin 25mg and 35mg capsules		NF-PA	New generics, adopting the Brand status. Standard strengths remain on-formulary.
Ivermectin (Sklice)	NF-PA	NF-PA	A standard update, to prefer the equivalent generic.
Ivermectin lotion		NF-PA	A new generic, adopting the Brand status.
Lopinavir/ ritonavir		F	A new generic, adopting the Brand status.
Ponesimod (Ponvory)		NF-PA-QL-SP	A new FDA-approval. Preferred alternatives are available.
Pregabalin ER		NF-PA-QL	A new generic, adopting the Brand status.
Relugolix/ estradiol/ norethindrone (Myfembree)		F-PA-QL-SP	A new FDA-approval
Rifaximin (Xifaxan)	F-PA	F-PA	PA update, clarifying coverage criteria.
Rilonacept (Arcalyst)	F-PA-SP	F-PA-SP	PA update, including a new indication for pericarditis.
Rufinamide tablet		F-PA-QL	A new generic, adopting the Brand status.
Sotorasib (Lumakras)		F-PA-SP-ONC	A new FDA-approval, added with standard oncology coverage criteria.
Tazarotene foam		NF-PA-QL	A new generic, adopting the Brand status.
Teriparatide		NF-PA-SP	A new generic for Bonsity, adopting the Brand status
Tesamorelin (Egrifta)	NF-PA-SP	NF-PA-SP	A drug for excess abdominal fat in HIV-infected patients with lipodystrophy.
Tiopronin		F-PA-SP	A new generic, adopting the Brand status.
Tivozanib (Fotivda)		F-PA-QL-SP-ONC	A new FDA-approval, added with standard oncology coverage criteria.
Topiramate (Qudexy XR)	NF-PA	NF-PA	Updating coverage criteria.
Topiramate (Trokendi XR)	NF-PA	NF-PA	Updating coverage criteria.
Viloxazine (Qelbree)		NF-PA	A new FDA-approval. Preferred alternatives are available.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, NC = Not Covered, SP = Specialty Drug, QL = Quantity Limit. ONC = Oncology medicine. A current formulary status is not shown for new medications.